Kazia Therapeutics announced it received a letter on May 22 from Nasdaq notifying the company that, while the company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the company is eligible for an additional 180 calendar day period, or until November 18, to regain compliance with the Minimum Bid Price Requirement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA: